Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (121-130 of 238) with videos related to

Pageof 24
Sort By:
Cancer Research|July 22, 2011
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancerXuemei Yang, Alexa B Turke, Jie Qi, et al.
Molecular Cancer Research : MCR|September 12, 2018
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant MelanomaGrace P Leung, Tianshu Feng, Frederic D Sigoillot, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2009
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionAnthony C Faber, Danan Li, Youngchul Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibRyohei Katayama, Luc Friboulet, Sumie Koike, et al.
Cell Reports|June 20, 2019
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor SensitivityLynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2016
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 SkippingRebecca S Heist, Lecia V Sequist, Darrell Borger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal MetastasesHironori Uruga, Emine Bozkurtlar, Tiffany G Huynh, et al.
The Journal of Clinical Investigation|October 12, 2011
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersHiromichi Ebi, Ryan B Corcoran, Anurag Singh, et al.
Journal of the National Cancer Institute|August 18, 2005
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutationsToru Mukohara, Jeffrey A Engelman, Nasser H Hanna, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.
Pageof 24

Showing results (121-130 of 238) with videos related to

Sort By:
Pageof 24
Cancer Research|July 22, 2011
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancerXuemei Yang, Alexa B Turke, Jie Qi, et al.
Molecular Cancer Research : MCR|September 12, 2018
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant MelanomaGrace P Leung, Tianshu Feng, Frederic D Sigoillot, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2009
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionAnthony C Faber, Danan Li, Youngchul Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibRyohei Katayama, Luc Friboulet, Sumie Koike, et al.
Cell Reports|June 20, 2019
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor SensitivityLynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2016
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 SkippingRebecca S Heist, Lecia V Sequist, Darrell Borger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal MetastasesHironori Uruga, Emine Bozkurtlar, Tiffany G Huynh, et al.
The Journal of Clinical Investigation|October 12, 2011
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersHiromichi Ebi, Ryan B Corcoran, Anurag Singh, et al.
Journal of the National Cancer Institute|August 18, 2005
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutationsToru Mukohara, Jeffrey A Engelman, Nasser H Hanna, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.
Pageof 24